Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timing of complete polyp regression after aflibercept in polypoidal choroidal vasculopathy
TCTR20181219003Phase 4Completed
- Sponsor
- Bayer
- Start
- Apr 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in polypoidal choroidal vasculopathy (PCV), sponsored by Bayer. Started Apr 2016; status: completed.
02
Drugs
aflibercept
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on TCTR20181219003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20181219003.